Oral immunization of raccoons and skunks with a canine adenovirus recombinant rabies vaccine.

Abstract

Oral vaccination is an important part of wildlife rabies control programs. Currently, the vaccinia-rabies glycoprotein recombinant virus is the only oral rabies vaccine licensed in the United States, and it is not effective in skunks. In the current study, captive raccoons and skunks were used to evaluate a vaccine developed by incorporating the rabies virus glycoprotein gene into a canine adenovirus serotype 2 vector (CAV2-RVG). Seven of 7 raccoons orally vaccinated with CAV2-RVG developed virus neutralizing antibodies and survived lethal challenge. Five of 5 and 6 of 6 skunks in 2 experimental groups receiving 10-fold different dilutions of CAV2-RVG developed neutralizing antibodies and survived challenge. The results of this preliminary study suggest that CAV2-RVG stimulates protective immunity against rabies in raccoons and skunks.

DOI: 10.1016/j.vaccine.2009.09.030

3 Figures and Tables

Statistics

02004002011201220132014201520162017
Citations per Year

288 Citations

Semantic Scholar estimates that this publication has 288 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Henderson2009OralIO, title={Oral immunization of raccoons and skunks with a canine adenovirus recombinant rabies vaccine.}, author={Heather A. Henderson and Felix R. Jackson and Kayla Bean and Brian Panasuk and Michael Niezgoda and Dennis Slate and Jianwei Li and Bernard Dietzschold and Jeff Mattis and C. Rupprecht}, journal={Vaccine}, year={2009}, volume={27 51}, pages={7194-7} }